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Background: Tardive dyskinesia (TD) is a potentially irreversible consequence of long term treatment with anti-
psychotic drugs which is according to a well-known theory believed to be related to oxidative stress induced
neurotoxicity. Dehydroepiandrosterone (DHEA) is an endogenous antioxidant with neuroprotective activity.
The biosynthesis of DHEA depends upon the activity of cytochrome P450c17α (CYP17). The gene that encodes
for CYP17 has a (T34C) single nucleotide polymorphism which enhances CYP17 transcription and expression.
Objective: To test the hypothesis that carriership of a more active CYP17 variant would result in higher DHEA(S)
levels and protect against neurotoxicity which results in orofaciolingual TD (TDof), limb-truncal TD (TDlt) or
both (TDsum).
Method: Tardive dyskinesia was assessed cross-sectionally in 146 Caucasian psychiatric inpatients from Siberia.
Results: Patients who are carriers of the Cyp17 genotype CC have less chance of developing TD compared to pa-
tientswho are carriers of the Cyp17 genotypes TCor TT (p b 0.05). However, these carriers have signiﬁcant lower
circulating DHEAS levels compared to carriers of the Cyp17 genotypes TC and TT (p b 0.05). Conversely, carriers
of the CYP17 T-allele have signiﬁcant elevated DHEAS levels. After correcting for gender and age no signiﬁcant
relationship between Cyp17 genotype CC, the T-allelle and the C-allele and the DHEAS concentration of patients
was observed.
Conclusions: Although an association between the CYP17 CC genotype and TD is indicated, our ﬁndings do not
support the hypothesis that this is mediated through increased DHEA(S) levels. We believe that the relationship
between this polymorphism and neuroprotective effects of steroids is more complex and cannot be elucidated
without taking the posttranslational regulation of the enzyme into account.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.AIMS, Abnormal Involuntary
, Dehydroepiandrosterone (sul-
imputation; TD, Tardive dyski-
b-truncal tardive dyskinesia;
del.
, Dept. of Pharmacy, Antonius
.: +31 50 363 7576; fax: +31
. Open access under CC BY-NC-ND lice1. Introduction
Tardive dyskinesia (TD) is a potentially irreversible drug-induced
movement disorder with a prevalence of about 20% in psychiatric pa-
tients chronically exposed to antipsychotics (Marsalek, 2000; Soares-
Weiser and Fernandez, 2007). Phenotypically, TD can be dissected into
two distinct subsyndromes: orofaciolingual (TDof) and limb-truncal
dyskinesias (TDlt). Accumulating evidence suggest that TDof and TDlt
are two distinct clinical entities with different clinical features, different
risk factors, different prognosis, and probably a different genetic liability
(Al Hadithy et al., 2009, 2010; Ivanova et al., 2012a,b).
The pathophysiology of TD has not yet been fully elucidated (Loonen
and Ivanova, 2013). Awell-known theory states that TD is related to ox-
idative stress induced dopaminergic neurotoxicity (Kulkarni and Naidu,
2003; Miyazaki and Asanuma, 2008). According to this theorynse.
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radical metabolism and the antioxidant defense mechanism (Cho and
Lee, 2013; Sayre et al., 2008). Among these antioxidant defense en-
zymes superoxide dismutase (SOD) plays a critical role in preventing
cell damage by free radicals. Several authors report a relatively consis-
tent association betweenmanganese SOD gene Ala-9Val polymorphism
with the susceptibility for developing TD (Bakker et al., 2008; Cho and
Lee, 2013). However, in their study and meta-analysis Zai et al. (2010)
did not replicate these ﬁndings. Possibly, this is at least partly related
to ethnic differences between the patient samples. In a previous study,
we found evidence for an association between Ala9Val (MnSOD) and
TDof, but not TDlt in the also currently studied Siberian Caucasian pa-
tients (Al Hadithy et al., 2010).
A second defense mechanism against oxidative stress-induced neu-
rotoxicity is the effect of neuroprotective steroids. One of these sub-
stances is dehydroepiandrosterone (DHEA), which is together with its
sulfate ester (DHEAS) one of the most abundant steroids in the human
body. Both DHEA and DHEAS have antioxidant effects (Camporez
et al., 2011; Gao et al., 2005; Maninger et al., 2009). Evidence also indi-
cates that DHEA and DHEAS are synthesized in the brain (Maninger
et al., 2009). DHEA is a 19-carbon steroid that is synthesized from cho-
lesterol by two steroidmetabolizing enzymes: P450scc and cytochrome
P450c17 (Maninger et al., 2009;Miller, 2005). The gene that encodes for
this cytochrome P450c17 alpha (17 alpha-hydroxylase; 17/20 lyase)
enzyme (CYP17) has a single nucleotide polymorphism, a T (A1)→ C
(A2) substitution at 34 base pair upstream of the translation initiation
site (T34C) (rs 743572) (Carey et al., 1994). The substitution was
thought to create an additional SP1-type (CCACC box) binding site in
promoter region, enhance CYP17 transcription, and expression. This
would result in higher DHEA levels. To our knowledge the relationship
between CYP17 (T34C) polymorphism and the TD has only been mea-
sured by Segman et al. (2002)withoutmeasuring DHEAS levels.We hy-
pothesized that the carriership of C allele would result in higher DHEAS
levels (in blood 99% of DHEA is present as its sulphate) and that this
would protect against neurotoxicity which results in TDof, TDlt or both.
2. Methods
2.1. Subjects
Informed consent was obtained from each subject after obtaining
approval of the study protocol by the institutional bioethics committee.
Subjects were included from two psychiatric departments (for perma-
nent and temporal hospitalization) of theMental Health Research Insti-
tute in Tomsk, Siberia (Russia).
We included subjects with clinical diagnosis of schizophrenia or
schizotypal disorder (ICD-10: F20 and F21, respectively) and excluded
subjects with non-Caucasian physical appearance (e.g., Mongoloid,
Buryats, or Khakassians), subjects on clozapine but without TD (cloza-
pine may ameliorate TD), subjects with clinically relevant withdrawal
symptoms and those with organic disorders.
2.2. Assessments
Clinical and demographic data were extracted from patients' medi-
cal ﬁles. TD was assessed cross-sectionally by the use of the Abnormal
Involuntary Movement Scale (AIMS). Four trained raters assessed the
presence of TD and, when present, the rating of TD was established by
consensus with either one of the two senior doctors. The presence of
TDof and TDlt was established by a cutoff AIMS score of ≥2 (mild but
deﬁnite) on any of the items 1 through 4 and 5 through 7, respectively.
The sum of the ﬁrst four items and of items 5 through 7 were used as a
proxy for the severity of TDof and TDlt, respectively, whereas the sum of
items 1 through 7 was used as a proxy for the severity of TDsum (Al
Hadithy et al., 2010).2.3. Medication
On the day of TD assessment, a complete documentation of themed-
ications utilized was compiled by the raters. The dose of the antipsy-
chotic medication was converted into chlorpromazine equivalents
(Rijcken et al., 2003).
2.4. DHEA
Since 99% of the circulating DHEA is present in its sulfated form, only
DHEAS serum levels (μg/mL) were measured. Blood samples were col-
lected by antecubital venapuncture between eight and nine o'clock in
the morning. The patients were instructed to abstain from unusual
physical activity or stress, 24 h before blood samples were taken. After
separation of serum by centrifugation, the samples were immediately
frozen and stored at−80 °C. The DHEAs levels were tested with aid of
the DHEA-S ELISA Kit (catalog number EIA1562, DRG International
Inc.). The range of analysis is 0.1–10 μg/mL, analytic sensitivity —
0.044 μg/mL. The DHEAS concentration in all samples were measured
in one analytic run in order to avoid inter-assay variability.
2.5. Genotyping
DNA extraction and ﬂuorogenic 5′-exonuclease TaqMan genotyping
assays were conducted according to standard protocols and blind to the
clinical status of the subjects (Al Hadithy et al., 2009, 2010). The CYP17
(T34C) (rs 743572) polymorphismwas genotyped by polymerase chain
reaction using an ampliﬁer real-time polymerase chain reaction system
7500 (Applied Biosystems).
2.6. Statistics
As in the beginning of this project no blood samples for the determi-
nation of DHEAS serum levels were collected, this data was absent in a
subgroup of 32 (22%) patients. These missing data was substituted by
means of a multiple imputation (MI) technique, which assumes that
the missing values are not completely missing at random. By this tech-
nique, the ranges of the plausible values of themissing DHEAs levels are
estimated based on other variables in the database. In this research the
variables age and genderwere used.Within the determined range,mul-
tiple values for DHEAS levels were calculated. This procedure was re-
peated 20 times, which ultimately resulted in 20 different data sets as
suggested by White et al. (2011). Each imputed data set was analyzed
using the standard analytical techniques. After these analyses, the de-
termined regression coefﬁcients and standard errors were averaged to
get a pooled estimate of the association (Donders et al., 2006;
Patrician, 2002).
For this study, a two part model (TPM) approach was used (Al
Hadithy et al., 2009) in order to deal with the clumping of zeroes
when measuring severity of TD. In the ﬁrst part of the two part model,
logistic regression analysis was used in order to determine whether
there is a signiﬁcant relation between the presence of TD, TDof and/or
TDlt and carriership of a certain Cyp17 genotype. Logistic regression
was also used in order to determine whether there is a signiﬁcant rela-
tion between the presence of TDsum, TDof and TDlt and carrier ship of a
certain Cyp17 allele (T or C). Both of these analyses were carried out be-
fore and after applying multiple imputation. In the second part of the
TPM approach, linear regression analysis was used to determinewheth-
er there is a signiﬁcant relation between the severity of TDsum, TDof
and TDlt and carriership of a certain Cyp17 genotype. For these analyses,
only the patients with TD were included. This analysis was carried out
after determining whether the distribution of the errors of variable
TDsum and/or log TDsum show a normal distribution by means of ap-
plying the Shapiro–Wilk test and the Kolmogorov–Smirnov test. There-
after, linear regression analysis was used to determine whether there is
a signiﬁcant relation between the severity of TDsum, TDof and TDlt and
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carried out before and after applying multiple imputation. The variable
DHEAs was taken into account in all analyses in order to determine
whether a correlation exists between the DHEAs levels of the patients
and carriership of a certain Cyp17 genotype or allele. The variable
DHEAs and some other variables of interest, like age, gender, type of
psychiatric clinic, use of anticholinergic and antipsychotic medication,
were selected in every approach by means of Akaike's Information Cri-
terion (AIC). The same explanatory variables were used before and
after multiple imputation. Finally, linear regression analysis was used
to determine whether there is a signiﬁcant relation between the level
of DHEAS in serum and the presence of TD, TDof or TDlt. Again this anal-
ysis was carried out after determination of normal distribution of errors
and before and after applying multiple imputation. Other variables of
interest in this analysis were age and gender.
The statistical software “R”was used for the calculations. For creat-
ing an overview of the clinical and demographic features of the study
population, excel and the statistical SPSS software, release 17, for Win-
dows were used. p values less than 0.05 were considered as signiﬁcant.
The deviation from theHardy–Weinberg equilibrium (HWE)was tested




3.1. Demographic and clinical features
In total 146 patientwere included ofwhich 91males and 55 females.
Demograpic and clinical details have been provided elsewhere (Al
Hadithy et al., 2009; Ivanova et al., 2012a). There is no signiﬁcant differ-
ence in average age and gender proportions between persons of which
the DHEAs values were available and persons with missing DHEAs
values.
3.2. Genotype and gender
An overview of the genotype distribution in the total population and
by gender shows that the female patients of this population are more
often carrier of the Cyp17 CC genotype compared to male patients
(Table 1). In contrast, the male patients are more often carriers of the
TT genotype. The genotype distribution of Cyp17 is not in consistency
with the Hardy–Weinberg equilibrium (p b 0.05).
3.3. CYP17 polymorphisms and the presence of TD variants
With logistic regression we determined whether a signiﬁcant rela-
tion existed between the presence of TDsum, TDof and TDlt and
carriership of a certain Cyp17 genotype or allele. The variables DHEAS,
age, gender, type of psychiatric center, use of anticholinergic and use
of antipsychotics were included in all models.
Logistic regression analysis of the inﬂuence of the Cyp17 genotypes
and theDHEAs level on the occurrence of TDsum, TDof and TDlt showed
that carriers of the Cyp17 genotypes TC and CC have no signiﬁcant in-
creased or decreased risk of developing TDsum, TDof or TDlt compared
to carriers of the Cyp17 genotype TT (data not shown). The same is true
for the inﬂuence of the serum concentration DHEAs of the patients.Table 1
Overview of the genotype distribution in the total population and by gender.
Genotype Total (146) Male (91) Female (55) HWE χ2 (p)
TT (A1A1) 63 (43.2%) 42 (46.2%) 21 (38.2%) 5.877 (0.015)
TC (A1A2) 55 (37.7%) 36 (39.6%) 19 (34.6%)
CC (A2A2) 28 (19. %) 13 (14.3%) 15 (27.3%)These effects are absent both before and after applying multiple
imputation.
However, the results of the logistic regression analysis of the inﬂu-
ence of the Cyp17 T-allele and the level of DHEAs on the occurrence of
TDsum, TDof and TDlt indicate that carriers of the Cyp17 genotype CC
have a signiﬁcant lower risk of developing TDsum compared to carriers
of the Cyp17 T-allele (p: 0.027). This effect is only observed before
adjusting for the level of DHEA and not for TDof and TDlt. Again, the
serum concentration of DHEAS has no inﬂuence on the development
of TDsum, TDof or TDlt, both before and after applying MI (Table 2).
Logistic regression analysis of the inﬂuence of the level of DHEAS and
the Cyp17 C-allele on the occurrence of TDsum, TDof and TDlt was again
without any signiﬁcant results. As amatter of fact, before multiple impu-
tation, the factor “genotype TT” is most times even identiﬁed by Akaike's
criterion as not explanatory for the model (data not shown).
3.4. Normality of the distribution of TD scores
To determinewhether there is a signiﬁcant relation between the se-
verity of TDsum, TDof and TDlt and carriership of a certain Cyp17 geno-
type or allele, linear regression analysis was used. Before these analyses
could be carried out, ﬁrst had to be determined whether the dependent
variable conforms to the assumption of normality for the errors. The re-
sults indicated that neither the errors of the TDsum scores nor their log
versions are normally distributed. However, the Shapiro–Wilk test gave
a better result with the variable log TDsum score than with the variable
TDsum score. In order to obtain accurate results, the following analyses
were performed with both the normal values and the log values of
TDsum scores.
3.5. Cyp17 polymorphism and the severity of TD variants
Linear regression analyses investigating the inﬂuence of DHEAS con-
centration and Cyp17 C-allele on the severity of TDsum, TDof and TDlt
showed that carriers of the genotypes TC, and CC do not experience a
signiﬁcantly more or less severe form of TDsum, TDof or TDlt compared
to carriers of the TT genotype. This effect is observed both before and
after applying MI and even when counted with the log variations of
TDsum, TDof and TDlt. The same is true for the relationship between
the serum concentration of DHEAS and the severity of TDsum, TDof or
TDlt. The inﬂuence of the level DHEAS on the severity of TD before MI
is however almost signiﬁcant (p: 0.054).
Linear regression analyses investigating the inﬂuence of DHEAS con-
centration and Cyp17 C-allele on the severity of TDsum, TDof and TDlt
shows that carriers of the genotype CC do not experience a signiﬁcant
more or less severe form of TDsum, TDof or TDlt compared to carriers
of the Cyp17 T-allele. This effect is observed both before and after apply-
ing MI and also when counted with the log variations of TDsum, TDof
and TDlt. Again, there is no signiﬁcant relation between the serum con-
centration of DHEAS and the severity. The inﬂuence of DHEAS on the se-
verity of TD before multiple imputation is as stated before almost
signiﬁcant (p: 0.054).
Linear regression analyses investigating the inﬂuence of DHEAS
concentration and Cyp17 C-allele on the severity of TDsum, TDof and
TDlt shows that carriers of the Cyp17 genotype TT do not experience a
signiﬁcantly more or less severe form of TDsum, TDof or TDlt compared
to carriers of the Cyp17 C-allele. Also in this analysis, there existed no
signiﬁcant relation between the serum concentration of DHEAS and
the severity of TDsum, TDof or TDlt. This effect is observed both before
and after applying MI and also when estimated using the transformed
values of TDsum, TDof and TDlt scores.
3.6. Cyp17 polymorphisms and DHEAS levels
Linear regression analyses investigating the inﬂuence of the Cyp17
genotypes and allele types on serum DHEAS levels show that there is
Table 2
Relationship between CYP17 genotypes/allele types and presence of TD and subtypes. Carriers T allele (TT + TC)/Non-carriers T allele (CC).
Nvar(n)/Ncom(n) TDsum estimate p value OR CI TDof estimate p value OR CI TDlt estimate p value OR CI
Before MI
DHEAS level excluded
CYP17 CC NCC(24)/NT(90) −1447 0.027 0.235 0.065–
0.849
−1151 0.080 0.316 0.087–
1.148
−1.513 0.159 0.220 0.027–1.810
Age – – – – – – – – – −0.048 0.008 1.049 0.988–0.920
DHEAS level included
CYP17 CC NCC(24)/NT(90) −3.230 0.094 0.040 b0.01–
1.723
−2.931 0.122 0.053 b0.01–
2.340
−7.373 0.230 b0.01 b0.01–104.9
DHEAS −0.059 0.738 0.943 0.669–
1.329
−0.058 0.755 0.943 0.659–
1.355
−0.066 0.758 0.936 0.702–1.625
After MI
CYP17 CC NCC(28)/NT(118) −3.067 0.106 0.047 b0.01–
1.925
−2.829 0.137 0.059 b0.01–
2.457
−6.783 0.261 b0.01 b0.01–156.6
DHEAS −0.048 0.776 0.953 0.683–
1.330
−0.048 0.786 0.953 0.672–
1.351
−0.075 0.717 0.928 0.719–1.614
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CC and the DHEAS concentrations of patients (p: 0.008) (Table 3). This
indicates that carriers of the Cyp17 genotype CC have signiﬁcant lower
DHEAS levels than carriers of the Cyp17 genotype TT. Also a signiﬁcant
positive relation (c: 0.364) was observed between the carriership of the
Cyp17 T-allele and the serum DHEAS levels (p: 0.024). Moreover, a sig-
niﬁcant negative relation (−0.299) is observed between carriers of the
Cyp17 C-allele and serum concentration of DHEAS (p: 0.026) (Table 3).
After adjusting the linear regression model for the effects of gender
and age on serum DHEAS levels no signiﬁcant relationship was ob-
served between the CYP17 genotype CC and the DHEAs concentrations
of patients. Also no signiﬁcant relationship was observed between
carriership of the Cyp17 genotype TC and the DHEAs levels of the pa-
tients. Neither a signiﬁcant relationship was present between
carriership of the Cyp17 T-allele nor of the Cyp17 C-allele and the
serum concentration of DHEAs.
4. Discussion
In the present study we investigated a possible association between
the occurrence of TDsum, TDof and TDlt, a T34C polymorphism in the
Cyp17 gene and circulating DHEAS levels in Slavonic Caucasians from
Siberia. The same patient population was studied in three otherTable 3
Relationship between Cyp17 genotypes/allele types and DHEAs levels before and after correcti
DHEAS level Nvar(n)/Ncom(n) Estim
Genotypes
CYP17 TC NTC(44)/NTT(46) −0.
CYP17 CC NCC(24)/NTT(46) −0.
T allele
Cyp17 T NT(90)/NCC(24) 0.
C allele
CYP17 C NC(68)/NTT(46) −0.












Gender 0.investigations (Al Hadithy et al., 2009, 2010; Ivanova et al., 2012a). In
the present study we observed that patients who are carriers of the
Cyp17 genotype CC have less chance of developing TD compared to pa-
tients who are carriers of the Cyp17 genotypes TC or TT. This is in line
with the expectation based on our hypothesis. This reduced risk of de-
veloping tardive dyskinesia in carriers of the CC genotype is not observ-
able when the two forms of tardive dyskinesia, TDof and TDlt, are
considered separately (Table 2). In addition, we observed that patients
who are carriers of the Cyp17 genotype CC have signiﬁcant lower circu-
lating DHEAS levels compared to carriers of the Cyp17 genotype TT
(Table 3). Conversely, carriers of the CYP17 T-allele have signiﬁcant el-
evated DHEAS levels. When the variables age and gender were included
into the calculations, the above described ﬁndings were no longer sig-
niﬁcant. However, the result was still nearly signiﬁcant, so a strong indi-
cation about a negative association between the Cyp17 genotype CC and
the DHEAs levels of these patients remains.
Our study has several limitations. Firstly, when we determined the
distribution of the Cyp17 genotypes in the population, this distribution
is not in consistency with the Hardy–Weinberg equilibrium (HWE).
This could possibly be caused by the small sample size. However, it is
also possible that there are other disturbing inﬂuences involved, like se-
lection bias. In that case, one of the Cyp17 genotypes provides a repro-
ductive advantage over the other genotypes. Deviations from the HWEng for variables age and gender.
ate p value OR CI
208 0.156 0.812 0.611–1.080
466 0.008 0.628 0.447–0.882
364 0.024 1.439 1.054–1.966
299 0.026 0.742 0.572–0.962
095 0.469 0.909 0.703–1.175
304 0.056 0.737 0.541–1.005
017 b0.001 0.983 0.976–0.989
185 0.127 1.203 0.950–1.523
255 0.076 1.290 0.976–1.707
018 b0.001 0.982 0.976–0.989
191 0.114 1.210 0.957–1.530
166 0.168 0.847 0.669–1.071
016 b0.001 0.984 0.976–0.989
199 0.101 1.220 0.964–1.543
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sume that this is the case. A second limitation is related to the cross-
sectional character of our study. We observed an association between
the genotype CC and the prevalence of TD on one hand and lower
DHEAS levels on the other hand. In both cases age and gender appears
to inﬂuence theﬁndings. Age and gender are important variables during
multiple imputation and have an important inﬂuence on the results.
Prospective stratiﬁed studies are needed to assess a possible causal rela-
tionship between CYP17 (T34C) genotypes and the development of TD.
A third possible limitationwould be the limited sample size for a genetic
study. However, this is certainly not a common genetic study. What we
tried to do in the present study is to develop a hypothesis and trying to
falsify it by measuring the genetic make-up of a limited number of pa-
tients with respect to a level-determining enzymatic activity. Therefore,
our study is not aimed at ﬁnding a gene that is associated with a certain
disease, but to test a hypothesis concerning the potential role of a phar-
macological mechanism in the development of dyskinesia. We hope
that our work will inspire other groups to use the tool of genetic associ-
ation study to test and try to falsify pharmacological hypotheses. It is a
far more efﬁcient than common association studies and a sound scien-
tiﬁc procedure.
Another limitation is related to nature of the enzyme studied. Cyto-
chrome P450c17 is a single enzyme with two activities: 17α-
hydroxylase and 17,20-lyase (Miller, 2005). The ﬁrst activity catalyzes
the 17α-hydroxylation of pregnenolone and the second converts 17-
OH-pregnenolone to DHEA. Initially, the observation that these two ac-
tivities were regulated independently led to the mistaken belief that
these were independent enzymes. However, the results of speciﬁc bio-
chemical and genetic studies showed that there exists only a single
P450c17 gene. In spite of this, the ratio of the 17,20 lyase to 17α-
hydroxylase activities varies and determines the amount of C21 to C19
steroids produced. This leads to the conclusion that this ratio is regulat-
ed posttranslational and at least threemechanismshave been suggested
to mediate these regulatory changes (Miller, 2005). This posttransla-
tional regulation may at least partly explain the controversy about the
clinical signiﬁcance of the CYP17 (T34C) polymorphism. Considerable
research efforts have for example been undertaken to demonstrate an
association between this polymorphism and the risk of breast cancer
(Chen and Pei, 2010). In this ﬁeld the polymorphism is believed to en-
hance CYP17 transcription, and expression, which would then be asso-
ciated with the increased estrogen levels and breast cancer risk.
However, the results of mutual investigations into this hypothesis are
conﬂicting. Several population characteristics have to be taken into ac-
count in order to be able to demonstrate an association between the
CYP17 (T34C) polymorphism and the risk of breast cancer (Chen and
Pei, 2010). Also in 259 women with polycystic ovary syndrome the
CYP17 (T34C) polymorphism was not found to play a signiﬁcant role
in determining the circulating DHEAS levels in comparison to 161 con-
trol patients (Kahsar-Miller et al., 2004).
The possibility of posttranslational regulation may also disturb the
relationship between the CYP17 (T34C) genotypes and DHEAS levels
on one hand and between these genotypes and TD on the other. The
measured DHEAS levels are too dependent upon the actual ratio of the
17,20 lyase to 17α-hydroxylase activities, and do not reﬂect the effec-
tive levels on the long term. Moreover, both pregnenolone (before)
and DHEA (after CYP17 biotransformation) are also metabolized to
other neuroactive steroids (progesterone, corticosterone, estradiol, tes-
tosterone), which could play an independent role.
In conclusion, we were not able to conﬁrm our hypothesis that the
CYP17 (T34C) polymorphism is contributing to the vulnerability to de-
velop TD by increasing the neuroprotective effects of DHEA. However,
we nevertheless observed an association between the CC carriership
and TD, which was also independent upon age and gender. Probably
the relationship between this polymorphism and neuroprotective ef-
fects of steroids is complex and cannot be elucidated without taking
the posttranslational regulation of the enzyme into account.Acknowledgments
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